



Number of metastatic sites < 2



Number of metastatic sites ≥ 2



Supplementary Figure S4. Survival difference stratified by the number of metastatic sites (< 2 vs. ≥ 2). (a–c) Progression-Free Survival (PFS), Overall Survival (OS) and Duration of Response (DOR) in the increased PD-1⁺CD8⁺ T-cell group (n = 22) and the decreased PD-1⁺CD8⁺ T-cell group (n = 23) among patients with fewer than two metastatic sites. (d–f) PFS, OS and DOR in the increased PD-1⁺CD8⁺ T-cell group (n = 6) and the decreased PD-1⁺CD8⁺ T-cell group (n = 17) among patients with more than two metastatic sites. The increased PD-1⁺CD8⁺ T-cell group showed longer PFS, OS and DOR among patients with fewer than two metastatic sites. (PFS: 9.6 months vs. 7.9 months, $p = 0.050$; OS: 26.4 months vs. 14.2 months, $p = 0.011$; DOR: 11.6 vs. 6.8 months, $p = 0.040$)